## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	DC	205/19
vvasiliilytuii,	D.C.	20049

STATEMENT	OF CHANGES	IN BENEFIC	IAL OWNERS	SHIP

l	OMB APPROVAL								
	OMB Number:	3235-0287							
l	Estimated average burd	en							
l	hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Finizio Robert G							2. Issuer Name <b>and</b> Ticker or Trading Symbol TherapeuticsMD, Inc. [ TXMD ]									ck all app	olicable)	ing Po		Owner
(Last) 6800 BR FLOOR	BROKEN SOUND PKWY NW, THIRD						3. Date of Earliest Transaction (Month/Day/Year) 08/20/2019								X	Offic below	,	CEO	below	(specify
,	ATON I			33487		4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person Form filed by More than One Reporting Person							
(City)	(	State		Zip) <b>e I - N</b> c	n-Deriv	ative	Sec	curitie	s Ac	nuired	. Dis	sposed o	f. or F	 Benefi	cially	/ Own	-d			
1. Title of Security (Instr. 3)  2. Tran Date				2. Transac	ction	tion 2A. Deemed Execution Date,		3. 4. Securit		4. Securitie	ies Acquired (A) or Of (D) (Instr. 3, 4 and			5. Amount of Securities Beneficially Owned Following		Forn (D) c	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership		
										Code	v	Amount	(A) (D)	Prio	e	Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)	
Common Stock 08/20/						2019	019			P		35,000	A	\$2	.74(1)	18,2	53,964		D	
Common Stock																1,00	04,941		T I	See Footnote <sup>(2)</sup>
Common Stock																995,059				See Footnote <sup>(3)</sup>
			Та									osed of, onvertib				Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversio or Exercis Price of Derivative Security	n D e (N	. Transaction ate Month/Day/Year)	3A. Deer Executic if any (Month/L	on Date,	4. Transa Code ( 8)					te Amor Secu Unde Deriv Secu		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)  Amount or Number of Title Shares		Price of erivative ecurity estr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	

## **Explanation of Responses:**

- 1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$2.70 to \$2.79 inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in Footnote (1) to this Form 4.
- 2. The reported securities are owned by the reporting person's Grantor-Retained Annuity Trust.
- 3. The reported securities are owned by Robert Finizio Revocable Trust.

/s/ Robert G. Finizio 08/20/2019

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.